GAAP Net Income of $0.67 per Unit Adjusted Net Income of $0.80 per Unit Cash Distribution of $0.80 per Unit NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today reported financial and operating results for the quarter ended March 31, 2025. "Against a tough market backdrop that intensified into the second quarter, all three of our global distribution channels grew organically, totaling $2.7 billion active net inflows ...

Core Viewpoint - The European Medicines Agency (EMA) has granted orphan drug designation to AB8939 for the treatment of acute myeloid leukemia (AML), indicating its potential significant benefit over existing therapies [1][2]. Group 1: Orphan Drug Designation - AB8939 previously received orphan drug designation from the US FDA, and the EU designation is a significant milestone, suggesting that it offers substantial benefits to AML patients [2]. - The criteria for orphan drug designation at EMA are stringent, requiring evidence of significant benefit compared to existing treatments [2][4]. Group 2: Efficacy and Safety Data - Preclinical data from mouse models show that AB8939 provides a significant benefit over current therapies like cytarabine, azacitidine, and venetoclax [3]. - Preliminary efficacy and safety data from Phase 1 trials indicate that AB8939 is effective as a monotherapy with different treatment cycles [3]. - AB8939 demonstrates efficacy against drug-resistant AML cells, with 45% of vincristine-resistant and 66% of cytarabine-resistant cells responding to treatment [4]. Group 3: Mechanism of Action - AB8939 is a synthetic molecule that targets cancer cells by destabilizing microtubules essential for cell division and inhibiting enzymes crucial for cancer stem cell survival [6]. - The chemical name of AB8939 is '1-{4-[2-(5-ethoxymethyl-2-methylphenylamino)-oxazol-5-yl]phenyl}imidazolidin-2-one' [6]. Group 4: Benefits of Orphan Drug Designation - Orphan drug designation in the EU provides various benefits, including scientific advice on product development, access to centralized marketing authorization, and potential financial incentives [8]. - If approved, AB8939 will enjoy 10 years of marketing exclusivity from the date of registration, provided the orphan designation remains valid [8].

Core Viewpoint - AllianceBernstein Holding L.P. (NYSE: AB) is rated as a Buy for investors focused on capital appreciation and long-term investments, with Q1 earnings expected to be declared on April 24th [1]. Company Summary - AllianceBernstein is anticipated to report its Q1 earnings soon, which is a significant event for investors [1]. - The company is positioned for long-term buy and hold strategies, appealing to capital appreciation-focused investors [1]. Analyst Background - David A. Johnson, the founder of Endurance Capital Management, has over 30 years of investment experience and holds advanced degrees in finance and business administration [1].

Core Viewpoint - AB Science has received a Notice of Allowance for a US patent covering the use of masitinib in treating sickle cell disease, providing protection until November 2040, which enhances its intellectual property portfolio [1][3]. Company Overview - AB Science is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) targeting diseases with high unmet medical needs [12][13]. Product Development - Masitinib is being developed as a treatment for severe forms of sickle cell disease, which accounts for approximately 65% of cases. The drug targets mast cells, which play a critical role in the disease's complications [3][4]. - The clinical development of masitinib in sickle cell disease is part of the SICKMAST collaborative program, which is funded with €9.2 million and aims to demonstrate efficacy in a phase 2 clinical trial [5]. Medical Need - Sickle cell disease is a significant public health challenge, with around 300,000 children born with the condition annually, potentially rising to 400,000 by 2050. The disease leads to early death and high social burden [6][10]. - Current treatment options do not fully prevent life-threatening complications, highlighting a significant medical need for effective therapies [10]. Scientific Insights - Masitinib has shown survival benefits in preclinical models, with treated mice experiencing no vaso-occlusive crises (VOC) or deaths, indicating its potential effectiveness [4]. - The drug acts as an inhibitor of key kinases involved in mast cell activation, which is crucial for addressing the inflammatory aspects of sickle cell disease [8][9].

NASHVILLE, Tenn., April 9, 2025 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management decreased to $784 billion during March 2025 from $805 billion at the end of February. Net inflows across all three channels (Institutional, Retail and Private Wealth) were offset by market depreciation during March, resulting in a 2.6% decline in month-end AUM. For the quarter-ended March 2025, preliminary firmwide ...

NASHVILLE, Tenn., April 7, 2025 /PRNewswire/ -- AllianceBernstein L.P. and AllianceBernstein Holding L.P. (NYSE: AB) today announced that First Quarter 2025 financial and operating results will be released before the market opens on Thursday, April 24, 2025. Management will conduct a teleconference beginning at 9:00 am (CT), to discuss the results. The call will be hosted by Seth Bernstein, President and Chief Executive Officer; Thomas Simeone, Chief Financial Officer; and Onur Erzan, Head of Global Client ...

Group 1 - The article emphasizes the importance of value investment and the search for bargain buys in stock analysis [1] - The analyst has over 20 years of experience in quantitative research, financial modeling, and risk management, focusing on equity valuation and market trends [1] - The investment approach combines risk management with long-term value creation, highlighting a keen interest in macroeconomic trends and corporate earnings [1] Group 2 - There is no disclosure of any stock, option, or derivative positions in the companies mentioned, indicating an unbiased perspective [2] - The article expresses personal opinions and does not provide compensation for the views expressed, ensuring independence in analysis [2] - Seeking Alpha clarifies that past performance does not guarantee future results, and the views may not reflect the platform's overall stance [3]

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Shares of AllianceBernstein (NYSE: AB ) have delivered a total return of 1% since my most recent upda ...

Core Viewpoint - The comparison between AllianceBernstein (AB) and Carlyle Group (CG) indicates that AB presents a better value opportunity for investors at this time due to stronger earnings estimate revisions and more attractive valuation metrics [1][3][7]. Valuation Metrics - AllianceBernstein has a forward P/E ratio of 10.69, while Carlyle Group has a forward P/E of 10.81 [5]. - The PEG ratio for AB is 0.84, indicating a more favorable expected earnings growth rate compared to CG's PEG ratio of 1.07 [5]. - AB's P/B ratio stands at 2.09, compared to CG's P/B ratio of 2.60, suggesting that AB is more undervalued relative to its book value [6]. Analyst Outlook - AB holds a Zacks Rank of 2 (Buy), reflecting a more positive analyst outlook due to stronger earnings estimate revision activity, while CG has a Zacks Rank of 3 (Hold) [3][7]. - The Value grade for AB is B, indicating it is considered undervalued, whereas CG has a Value grade of C [6].

Core Insights - AllianceBernstein L.P. reported a decrease in preliminary assets under management (AUM) to $805 billion in February 2025, down from $809 billion at the end of January, marking a 0.5% decline driven entirely by market depreciation [1] - Firmwide net flows were flat in February, with net inflows into Private Wealth being offset by Institutional net outflows, while Retail flows remained unchanged [1] AUM Breakdown - As of February 28, 2025, the total AUM was $805 billion, with a breakdown as follows: - Total Equity: $333 billion, down from $342 billion in January - Total Fixed Income: $303 billion, up from $299 billion in January - Alternatives/Multi-Asset: $169 billion, slightly up from $168 billion in January [2][3] Channel Performance - Private Wealth AUM stood at $140 billion, unchanged from January - Institutional AUM decreased to $328 billion from $327 billion in January - Retail AUM decreased to $337 billion from $343 billion in January [3]